PPD claims top China CRO title as it opens vax center

PPD has opened a new vaccine research center in the heart of China's sprawling biotech hub, staking its claim as the biggest CRO in China on the same day that Charles River Laboratories unveiled its $1.6 billion acquisition of WuXi PharmaTech. PPD opened the research complex in Taizhou China Medical City so it can host vaccine trials that require far more people than most other countries demand for a vax trial but with a far shorter amount of time needed for enrollment. "The vaccines market is...